Sign In
Buy ATNM
$1.11
-0.0500 (-4.31%)
At Close: Jun 04, 2026
Atossa Genetics (ATOS) Gets a Buy Rating from Maxim Group
05:16pm, Tuesday, 28'th Apr 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Atossa Genetics (ATOS) today and set a price target of $4.00. The company's shares closed last
Atossa Genetics (ATOS) Gets a Buy Rating from Maxim Group
05:16pm, Tuesday, 28'th Apr 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Atossa Genetics (ATOS – Research Report) today and set a
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the closing of the Company's previously announced underwritten public offering of 210,833,334 shares
Actinium Pharmaceuticals, Inc. Announces Closing of $'–. ...
12:00am, Friday, 24'th Apr 202070 Biggest Movers From Yesterday
08:12am, Thursday, 23'rd Apr 2020
Gainers
SAExploration Holdings, Inc. (NASDAQ: SAEX) shares surged 98.2% to close at $2.22 on Wednesday after the company disclosed a new project in Greece.
The Peck Company...
Mid-Morning Market Update: Markets Open Higher; Kimberly-Clark Beats Q1 Expectations
02:12pm, Wednesday, 22'nd Apr 2020The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership
11:51am, Wednesday, 22'nd Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Ar
Inmune Bio (INMB) Gets a Buy Rating from Maxim Group
11:30am, Wednesday, 22'nd Apr 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Inmune Bio (INMB) today and set a price target of $13.00. The company's shares closed last
Inmune Bio (INMB) Gets a Buy Rating from Maxim Group
11:29am, Wednesday, 22'nd Apr 2020
Maxim Group analyst
Jason McCarthy
assigned a
Buy
rating to Inmune Bio (
INMB
–
Research Report
) today and set a price target of
$13.00
. The company’s shares closed last Tuesday at $4.27.
Accord
Actinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public Offering
03:35am, Wednesday, 22'nd Apr 2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the pricing of the Company's previously announced underwritten public offering of 183,333,334 shares
Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering
08:01pm, Tuesday, 21'st Apr 2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase comm
Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering; Terms Not Disclosed
12:00am, Tuesday, 21'st Apr 2020Maxim Group Releases a Hold Rating on Gilead Sciences (GILD)
12:51pm, Saturday, 18'th Apr 2020
Maxim Group analyst Jason McCarthy assigned a Hold rating to Gilead Sciences (GILD – Research Report) today. The company’s shares
Atossa Genetics (ATOS) Receives a Buy from Maxim Group
04:47pm, Friday, 17'th Apr 2020
In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Atossa Genetics (ATOS), with a price target of $4.00. The company's
